Claims:

1. Use of an isolated antibody or binding fragment thereof in the manufacture of a medicament for treating rheumatoid arthritis in a subject previously ineffectively treated for rheumatoid arthritis by the administration of TNF-α antagonist wherein the isolated antibody or binding fragment thereof comprises the heavy chain variable region of sequence SEQ ID NO:2 and the light chain variable region of sequence SEQ ID NO:3,
wherein said antibody or binding fragment thereof is formulated to be administered subcutaneously to the subject in a dosage of 150 mg or 200 mg, and wherein the antibody or binding fragment thereof is to be administered sequentially or simultaneously with methotrexate.

2. The use according to claim 1, wherein said methotrexate is to be administered in a dosage of between 6-25 mg.

3. The use according to claim 2, wherein said medicament is to be administered to a subject suffering from rheumatoid arthritis wherein a previous administration of methotrexate and a TNF-α antagonist to said subject was ineffective.

4. The use according to claims 1 to 3, wherein said medicament achieves at least a 20% improvement in the American College of Rheumatology core set disease index.

5. The use according to claim 4, wherein said medicament achieves at least a 50% improvement in the American College of Rheumatology core set disease index.

6. The use according to claim 5, wherein said medicament achieves at least a 70% improvement in the American College of Rheumatology core set disease index.

7. The use according to any one of claims 1 to 6, wherein said medicament is to be administered to said subject for at least 12 weeks.

8. The use according to any one of claims 3 to 7, wherein said TNF-α antagonist is selected from the group consisting of etanercept, infliximab, adalimumab, golimumab and certolizumab pegol.

9. The use according to any one of claims 3-8, wherein said medicament is effective for administration to a subject suffering from rheumatoid arthritis wherein a previous administration of a TNF-α antagonist to said subject was ineffective for at least 3 months or the subject was intolerant to at least one TNF-α antagonist.

10. The use according to any one of claims 1 to 9, wherein said antibody is sarilumab.